Companies › Stoke Therapeutics
1 active drug program in 2 registered trials: 1 Phase 3, 1 Phase 2; Neurology; next expected readout Mar 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| zorevunersen antisense oligonucleotide targeting SCN1A | Ion channels | Phase 3 | Dravet Syndrome | Mar 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06872125 | zorevunersen | Phase 3 | Dravet Syndrome | Neurology | Mar 2027 |
| NCT04740476 | zorevunersen | Phase 2 | Dravet Syndrome | Neurology | Mar 2029 |
Cash and short-term investments of $319m on 2026-09-30; operating cash outflow about $241m a year; runway about 16 months at that burn, to Jan 2028; 1 of 2 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 8 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Capricor Lupin Dyne Therapeutics Navamedic Danyang Huichuang Medical Equipment
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.